nk 611 has been researched along with Lung Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gemba, K; Kiura, K; Matsumura, T; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M | 1 |
1 trial(s) available for nk 611 and Lung Neoplasms
Article | Year |
---|---|
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia | 1996 |
1 other study(ies) available for nk 611 and Lung Neoplasms
Article | Year |
---|---|
[In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Division; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1993 |